The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback